At 8.2% CAGR, the Asia Pacific Coagulation Market is Projected to be Worth US$ 1,672.49 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Asia Pacific coagulation market was valued at US$ 889.52 million in 2022 and is expected to reach US$ 1,672.49 million by 2030, registering a CAGR of 8.2% from 2022 to 2030. Rising prevalence of cardiovascular diseases and increasing prevalence of blood disorders are among the critical factors attributed to the Asia Pacific coagulation market expansion.

Heart disease is one of the leading causes of hospitalization, death, and reduced physical performance due to conditions such as atrial fibrillation and stroke. It affects the hemostatic system, vascular system, and fluid dynamics of blood and causes arterial and venous thrombosis. Thrombosis is the leading cause of death and complications from cardiovascular disease. Blood vessels damaged by smoking and high blood pressure form cholesterol-rich plaques lining the blood vessels, which can rupture and cause platelets to clot. With coagulation disorders, there is a risk of myocardial infarction, stroke, and atherothrombotic events in the vascular beds. Heart failure (HF) is related to an increased risk of thromboembolism independent of the presence of atrial fibrillation (AF). Platelet activation and coagulation system abnormalities can increase the risk of serious thromboembolic events in patients suffering from HF.

As per 'Global Burden of Disease Study 2019,' CVDs were the leading cause of deaths in Asia Pacific in 2019, causing 10.8 million or 35% of the total fatalities.

A coagulation test helps prevent potential heart attack-causing blood clotting. A coagulation analyzer is used during coronary artery bypass surgery and angioplasty to monitor information on blood clotting status. Thus, the growing incidence of cardiovascular diseases bolsters the coagulation market growth.

On the contrary, high costs associated with coagulation analyzers hampers the growth Asia Pacific coagulation market.

Based on disease indication, the Asia Pacific coagulation market is segmented into vitamin k deficiency, liver disease, disseminated intravascular coagulation and pulmonary embolism, development of circulating anticoagulants, hemophilia, von willebrand's disease, and others. The liver disease segment held 53.9% share of the Asia Pacific coagulation market in 2022, amassing US$ 479.79 million. It is projected to garner US$ 890.13 million by 2030 to expand at 8.0% CAGR during 2022-2030.

Based on type, the Asia Pacific coagulation market is bifurcated into clinical laboratory analysers and point-of-care testing analyzers. The clinical laboratory analysers segment held 66.0% share of the Asia Pacific coagulation market in 2022, amassing US$ 586.79 million. It is projected to garner US$ 1,055.37 million by 2030 to expand at 7.6% CAGR during 2022-2030. Clinical laboratory analysers is further subsegmented into controls & calibrators, assays & reagents, instruments/systems, coagulation factors, and others.

In terms of offering, the Asia Pacific coagulation market is bifurcated into diagnosis and treatment. The diagnosis segment held 64.8% share of the Asia Pacific coagulation market in 2022, amassing US$ 576.59 million. It is projected to garner US$ 1,070.80 million by 2030 to expand at 8.0% CAGR during 2022-2030. Diagnosis is further subsegmented into prothrombin time testing, fibrinogen testing, activated clotting time testing, activated partial thromboplastin time testing, d-dimmer testing, platelets function testing, and others. Treatment is further subsegmented into anti-fibrinolytic drugs, birth control pills, desmopressin & immunosuppressive medicines, vitamin k supplements, blood thinners, thrombin inhibitors or thrombolytics, replacement therapy, catheter-assisted thrombus removal, and others.

By technology, the Asia Pacific coagulation market is segmented into optical technology, mechanical technology, electrochemical technology, and others. The optical technology segment held 61.0% share of Asia Pacific coagulation market in 2022, amassing US$ 542.48 million. It is projected to garner US$ 1,029.88 million by 2030 to expand at 8.3% CAGR during 2022-2030.

By end user, the Asia Pacific coagulation market is segmented into clinical laboratories, hospitals, and others. The hospitals segment held 60.4% share of Asia Pacific coagulation market in 2022, amassing US$ 537.04 million. It is projected to garner US$ 1,024.27 million by 2030 to expand at 8.4% CAGR during 2022-2030.

Based on country, the Asia Pacific coagulation market is categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China held 30.4% share of Asia Pacific coagulation market in 2022, amassing US$ 270.80 million. It is projected to garner US$ 517.62 million by 2030 to expand at 8.4% CAGR during 2022-2030.

Key players operating in the Asia Pacific coagulation market are F. Hoffmann-La Roche Ltd; Genrui Biotech Co., Ltd; Horiba Ltd; ImproGen Diagnostik Kimya San & Tic Ltd.Şti; Siemens Healthineers AG; Sysmex Corp; and Transasia Bio-Medicals Ltd, among others.

• In Feb 2021, Siemens Healthineers and Sysmex Extend Hemostasis Agreement. Siemens Healthineers and Sysmex Corporation announced the renewal of the companies' long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis products including a multi-year extension. As part of the agreement Siemens Healthineers will distribute the new Sysmex CN Systems.
  
  
• In Aug 2021, Siemens Healthineers Launched Sysmex CN-3000 and CN-6000 Hemostasis Systems. This fully automated CN-3000 and CN-6000 Systems bring mid- and high-volume coagulation testing to laboratories.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com